SYMPTOM CONCERNS AND QOL IN PATIENTS WITH OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHY

2.50
Hdl Handle:
http://hdl.handle.net/10755/164881
Category:
Abstract
Type:
Presentation
Title:
SYMPTOM CONCERNS AND QOL IN PATIENTS WITH OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHY
Author(s):
Sun, Virginia; Ferrell, Betty; Otis-Green, Shirley; Shibata, Stephen; Juarez, Gloria; Choi, Kyong
Author Details:
Virginia Sun, RN MSN, Senior Research Specialist, City of Hope National Medical Center, Duarte, California, USA, email: vsun@coh.org; Betty Ferrell, RN, PhD, FAAN; Shirley Otis-Green, MSW, ACSW, LCSW, OSW-C; Stephen Shibata, MD; Gloria Juarez, RN, PhD; Kyong Choi, MA, Vital Research, Los Angeles, California
Abstract:
Standard chemotherapeutic regimens for colorectal cancer (CRC) often utilize multiple agents with toxicities that may impact QOL both acutely and chronically. Oxaliplatin-induced peripheral neuropathy, a dose-limiting toxicity, is common in CRC and may impact QOL. The purpose of this study was to describe the symptom concerns of CRC patients with oxaliplatin-induced peripheral neuropathy and explore the impact of symptoms on patientÆs QOL. This study addressed the priority topic of increasing the understanding and management of understudied symptoms such as peripheral neuropathy. Study framework is based upon the COH QOL model and on the FACIT model. The framework demonstrates that symptom concerns may impact QOL across the domains of physical, social, emotional, and functional well-being. This prospective, longitudinal study incorporated a mixed-methods design to gain insight into participantÆs experience with peripheral neuropathy. Sixty-three CRC patients treated with oxaliplatin were accrued, and 20 semi-structured interviews were conducted. Participants were followed from treatment initiation and at 24 hours, 1 week, 1 month, and 2 months post-initiation. Outcome measures included the FACT-C, FACT/GOG-Ntx, and Neuropathic Pain Scale. Toxicity grading was documented using the NCI-CTC and Oxaliplatin Specific Scale. Data analysis was derived through descriptive design of quantitative symptom reports along with simultaneous regression method to determine variance in QOL. Qualitative data was interpreted through content analysis methods. Mean age of subjects was 60, and ethnicity included 61% Caucasian, 14% Hispanic, 11% Asian, and 6% African American. Subjects included 22% Stage III and 29% Stage IV disease of which 45% were undergoing treatment for initial diagnosis and 14% were undergoing treatment for recurrent disease. All participants were oxaliplatin- nanve at baseline. Subjects identified symptom concerns in the physical (30%), emotional (40%), and functional (30%) domains of QOL. Grade I neuropathy was seen in 47%, Grade II in 13%, and Grade III in 1.6% of participants. Qualitative data indicated that peripheral neuropathy was tolerable but had some impact on functional status for participants. The identification of specific symptom concerns in oxaliplatin-induced peripheral neuropathy will enhance clinical understanding of the symptom and aid in the future development of nursing interventions for this patient population.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleSYMPTOM CONCERNS AND QOL IN PATIENTS WITH OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHYen_GB
dc.contributor.authorSun, Virginiaen_US
dc.contributor.authorFerrell, Bettyen_US
dc.contributor.authorOtis-Green, Shirleyen_US
dc.contributor.authorShibata, Stephenen_US
dc.contributor.authorJuarez, Gloriaen_US
dc.contributor.authorChoi, Kyongen_US
dc.author.detailsVirginia Sun, RN MSN, Senior Research Specialist, City of Hope National Medical Center, Duarte, California, USA, email: vsun@coh.org; Betty Ferrell, RN, PhD, FAAN; Shirley Otis-Green, MSW, ACSW, LCSW, OSW-C; Stephen Shibata, MD; Gloria Juarez, RN, PhD; Kyong Choi, MA, Vital Research, Los Angeles, Californiaen_US
dc.identifier.urihttp://hdl.handle.net/10755/164881-
dc.description.abstractStandard chemotherapeutic regimens for colorectal cancer (CRC) often utilize multiple agents with toxicities that may impact QOL both acutely and chronically. Oxaliplatin-induced peripheral neuropathy, a dose-limiting toxicity, is common in CRC and may impact QOL. The purpose of this study was to describe the symptom concerns of CRC patients with oxaliplatin-induced peripheral neuropathy and explore the impact of symptoms on patientÆs QOL. This study addressed the priority topic of increasing the understanding and management of understudied symptoms such as peripheral neuropathy. Study framework is based upon the COH QOL model and on the FACIT model. The framework demonstrates that symptom concerns may impact QOL across the domains of physical, social, emotional, and functional well-being. This prospective, longitudinal study incorporated a mixed-methods design to gain insight into participantÆs experience with peripheral neuropathy. Sixty-three CRC patients treated with oxaliplatin were accrued, and 20 semi-structured interviews were conducted. Participants were followed from treatment initiation and at 24 hours, 1 week, 1 month, and 2 months post-initiation. Outcome measures included the FACT-C, FACT/GOG-Ntx, and Neuropathic Pain Scale. Toxicity grading was documented using the NCI-CTC and Oxaliplatin Specific Scale. Data analysis was derived through descriptive design of quantitative symptom reports along with simultaneous regression method to determine variance in QOL. Qualitative data was interpreted through content analysis methods. Mean age of subjects was 60, and ethnicity included 61% Caucasian, 14% Hispanic, 11% Asian, and 6% African American. Subjects included 22% Stage III and 29% Stage IV disease of which 45% were undergoing treatment for initial diagnosis and 14% were undergoing treatment for recurrent disease. All participants were oxaliplatin- nanve at baseline. Subjects identified symptom concerns in the physical (30%), emotional (40%), and functional (30%) domains of QOL. Grade I neuropathy was seen in 47%, Grade II in 13%, and Grade III in 1.6% of participants. Qualitative data indicated that peripheral neuropathy was tolerable but had some impact on functional status for participants. The identification of specific symptom concerns in oxaliplatin-induced peripheral neuropathy will enhance clinical understanding of the symptom and aid in the future development of nursing interventions for this patient population.en_GB
dc.date.available2011-10-27T12:08:39Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:08:39Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.